| Term 
 
        | what are the constraints that make anxiety normal |  | Definition 
 
        | brief event related
 unconcious, no control
 |  | 
        |  | 
        
        | Term 
 
        | what are symptoms of anxiety |  | Definition 
 
        | muscle tone sweating
 tachycardia
 tachypenia
 weakness
 irritability
 fatigue
 |  | 
        |  | 
        
        | Term 
 
        | what are the two rules of diagnozing generalized anxiety disorder |  | Definition 
 
        | symptoms >6 mo 3+ symptoms from the list
 |  | 
        |  | 
        
        | Term 
 
        | what are the symptoms of generalize anxiety disorder |  | Definition 
 
        | excessive anxiety worry that is difficult to control
 feeling on edge
 poor concentration/ mind blanking
 restlessness, fatigue, sleep disturbance
 muscle tension, irrtability
 social, occupation, functional impairment
 poor coping abilities
 |  | 
        |  | 
        
        | Term 
 
        | what is the non-medication tx for generalized anxiety disorder |  | Definition 
 
        | psycho-education short term councling
 stress management
 psycho-therapy
 exercise
 |  | 
        |  | 
        
        | Term 
 
        | what medications are used to tx acute anxiety, why, what redigmen |  | Definition 
 
        | BZD for 2 weeks most effective, safe, rapid
 |  | 
        |  | 
        
        | Term 
 
        | what medications are used to treat chronic anxiety (4) |  | Definition 
 
        | SSRI, SNRI, TCA, buspirone |  | 
        |  | 
        
        | Term 
 
        | what medication is used to tx anxiety in kids under 12 (1) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what medications are used to treat anxiety in elderly (3) |  | Definition 
 
        | burpirone lorazepam
 osazepam
 |  | 
        |  | 
        
        | Term 
 
        | what medications are used to tx anxiety in hepatic failure (2) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is the map of tx for chronic anxiety |  | Definition 
 
        | venlafaxine or SSRI no effect: switch
 no effect: imipramine, busprione, hydroxyzine, pregalbalin, duloxetine
 no effect: BZD 2-4 weeks
 |  | 
        |  | 
        
        | Term 
 
        | what are syptoms of panic disorder |  | Definition 
 
        | depersonalization de-realization
 fear of loosing control
 fear of going crazy
 fear of dying
 abdominal distress, chest pain, chills, dizzy, choking, hot flashes, palpitations, nausea, paresthesias, SOB, sweating, tachycardia, trembling
 |  | 
        |  | 
        
        | Term 
 
        | what is the non-medication tx for panic disorder |  | Definition 
 
        | avoid percipitating substances (caffiene, stimulants) cognative behavorial therapy
 self help books
 exercise
 |  | 
        |  | 
        
        | Term 
 
        | what medicine is used for acute/urgent panic dosorder |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is the map of tx for chronic panic disorder |  | Definition 
 
        | SSRI or venlafaxine no effect: switch or try imipramine
 no effect: BZD, pindolol, anti-depressant
 |  | 
        |  | 
        
        | Term 
 
        | what are the signs of SAD |  | Definition 
 
        | intense irrational persistant fear of being negativley evaluated, scrutinized, or embarrased fear of adressing group, eating with others, interacting with authority, talking to strangers, using public toiles
 
 blushing, butterflies, diarrhea, sweating, tachycardia, trembling
 |  | 
        |  | 
        
        | Term 
 
        | what are the two types of SAD, describe them |  | Definition 
 
        | generalized: avoids wide range of social stituations 
 non-generalized: fear limited to specific situations
 |  | 
        |  | 
        
        | Term 
 
        | what is the non-medicine tx for SAD |  | Definition 
 
        | cognative behavorial therapy for several months in a group |  | 
        |  | 
        
        | Term 
 
        | what medicines are used to tx SAD |  | Definition 
 
        | antidepressants: SSRI (paroxetine), SNRI BZD (clonazepam)
 GABA analog: gabapentin, pregabaline
 B-blocker for "performance" one hour prior
 |  | 
        |  | 
        
        | Term 
 
        | what are the conditions for diagnosis of PTSD |  | Definition 
 
        | exposure to traumatic event (witness, experienced, confronted with sutation possible harm) with response of fear, helplessness, horror |  | 
        |  | 
        
        | Term 
 
        | what is the map of tx for PTSD |  | Definition 
 
        | SSRI (sertaline) for 12 mo no response: different SSRI, venlafaxine XR
 no response: TCA, mirtazapine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | patients are secretative, hard to diagnosed often have eczema, chapped skin
 compulsive hand washing or teeth brushing
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | what anxiety drug can be used in those with substance abuse problems |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | y-aminobutyric acid (GABA) opens Cl channel causing hyperpolarization at post-synapse inhibiting action potential 
 drug binds to receptors next to GABA receptors increasing GABA affinity (allosteric modulation) causing more Cl channel opening and further inhibition
 |  | 
        |  | 
        
        | Term 
 
        | what are the two types of BDZ and what are they involved with |  | Definition 
 
        | BZ1: deals with sleep BX2: deals with memory, cognative function, muscles, anti-convulsant, ataxia, emotion, anxiolytic
 |  | 
        |  | 
        
        | Term 
 
        | which BDZ has a different MOA, why |  | Definition 
 
        | chlorazepate: prodrug that turns into active metabolite |  | 
        |  | 
        
        | Term 
 
        | what are the short acting BDZ, how long |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what and the intermediate acting BDZ, how long |  | Definition 
 
        | Lorazepam alprazolam
 10-20h
 |  | 
        |  | 
        
        | Term 
 
        | what are the long acting BDZ, how long |  | Definition 
 
        | chlordiazepoxide diazepam
 chlorazepate
 1-3d
 |  | 
        |  | 
        
        | Term 
 
        | can you use BDZ in pregnancy, why |  | Definition 
 
        | no, crosses placenta and breast milk |  | 
        |  | 
        
        | Term 
 
        | what are the main side effects ob BDZ |  | Definition 
 
        | drowsiness confusion
 ataxia and fine motor loss
 congative impairment (long term recall, new learning)
 potentiate alcohol (CNS depressant)
 tolerance with time
 withdwarl
 |  | 
        |  | 
        
        | Term 
 
        | what occurs in BDZ withdrawl |  | Definition 
 
        | anxiety insomnia
 irritability
 weakness
 
 severity is drug and dose dependant
 avoid with titration
 |  | 
        |  | 
        
        | Term 
 
        | where does BDZ distribute to |  | Definition 
 
        | lipid soluble: goes to brain and perused organs first |  | 
        |  | 
        
        | Term 
 
        | where and when and how is BDZ metabolized |  | Definition 
 
        | metabolized to water soluble in liver before elimination 
 oxidation, hydroxylation, conjugation with glucuronic acid
 |  | 
        |  | 
        
        | Term 
 
        | where and when is BDZ excreted |  | Definition 
 
        | after metabolized in urine |  | 
        |  | 
        
        | Term 
 
        | what BDZ have different metabolism, why |  | Definition 
 
        | lorazepan and oxazepam bipass liver oxidation and have shorter half life |  | 
        |  | 
        
        | Term 
 
        | what substances can reduce oxidation of BDZ in liver |  | Definition 
 
        | liver disease cimetidine
 contraceptives
 |  | 
        |  | 
        
        | Term 
 
        | what drug is a benzodiazepine antagonist |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds to sites to competitavly antagonize allosteric effect of BDZ |  | 
        |  | 
        
        | Term 
 
        | why would you use fulamazenil |  | Definition 
 
        | BDZ over dose or side effects |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | partial agonist to 5HT receptors in limibc which activate G receptors and open K channel hyperpolarizing and decreasing firing |  | 
        |  | 
        
        | Term 
 
        | side effects of buspirone |  | Definition 
 
        | little CNS depression, motor effect, muscle relaxing, anti-convulsant 
 no physical dependance or withdrawl
 
 headache, dizziness
 |  | 
        |  | 
        
        | Term 
 
        | which anxiety drugs have slowest onset |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are two SSRI are for anxiety |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit re-uptake of serotonin at transporter blocking removal increases concentration at synaptic cleft
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | no dependance, withdrawl, CNS depression alcohol potentiation 
 insomnia, tremor, palpitations, vasldilation, NVD, loss of lobido
 
 paroxetine: postural hypotension
 
 anorexia, nausea, vomiting, diarrhea
 
 loss of libido, sexual dysfunction
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | SSRI metabolizm and excretion |  | Definition 
 
        | metabolized in liver excreted in feces and urine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cimetidine increase half life MAOI can be fatal (wait 14 d for switch)
 
 TCA inhibits metabolism
 
 tryptophan increases serotonin effect
 
 warfarin increases bleeding risk
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | venlafaxine duloxetine
 desvenlafaxine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | block serotonin and NE re-uptake transporters |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | simillar to SSRI 
 hypertension
 
 do not abruptly DC, slowly titrate due to BP effects
 |  | 
        |  | 
        
        | Term 
 
        | what are the anti-histamine anxiety drugs |  | Definition 
 
        | Piperazine Deratives... Hydroxyzine HCl
 Kydroxyzine Pamoate
 |  | 
        |  | 
        
        | Term 
 
        | MOA anti-histamine anxiety drugs |  | Definition 
 
        | antagonizes H1 receptor (excitatory) located in hippocampus and cortex |  | 
        |  | 
        
        | Term 
 
        | side effects of anti-histamine anxiety drugs |  | Definition 
 
        | sedation do not combine with alcohol
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | blocks pre-synaptic autoreceptors for NE and 5HT and increases NE and 5HT at synapse |  | 
        |  | 
        
        | Term 
 
        | in who is depression most common |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | define unipolar depression |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is the most common form of depression |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are signs of depression |  | Definition 
 
        | affective, cognative, motor, somatic prominent and persistent symptoms
 anhedonia
 insomnia
 fatigue
 worthlessness andguild
 inability to concentrate
 thoughts of death or suicide
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | loss of interest in activities |  | 
        |  | 
        
        | Term 
 
        | what is the prognosis of depression |  | Definition 
 
        | usually does not reoccur once subsides 10-15% suicide
 40-50% improve with tx
 |  | 
        |  | 
        
        | Term 
 
        | what do you do if someone has reoccuring depression |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | signs of manic depression |  | Definition 
 
        | eophoric mooods pressured speech
 psychomotor aggitation
 distractability
 insomnia
 severe depression spells
 |  | 
        |  | 
        
        | Term 
 
        | why shouldnt you use paroxetine in eldery |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | which SSRI are for depression |  | Definition 
 
        | citalopram escitalopram
 paroxetine
 sertaline
 fluxetine
 |  | 
        |  | 
        
        | Term 
 
        | which SSRI are for SAD, PTSD, OCD, which is PTSD DOC |  | Definition 
 
        | paroxetine sertaline - PTSD DOC
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | depression chronic anxiety
 chronic panic
 SAD
 PTSD
 |  | 
        |  | 
        
        | Term 
 
        | uses of piperazine derivatives |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | side effects of Mirtazapine |  | Definition 
 
        | sedation 1% incidence of agranulocytosis
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | chronic anxiety depression
 PTSD
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit serotonin reuptake (less than SSRI) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | little anticholinergic, hypotension, and CV effects 
 more safe than TCA
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit dopamine and NE reuptake |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stimulating, dont take at bed time |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are the atypical anti-depressants |  | Definition 
 
        | bupropion trazodone
 mirtazapine
 |  | 
        |  | 
        
        | Term 
 
        | 3 tricyclic antidepressants |  | Definition 
 
        | imipramine amitripryline
 clomipramine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | block NA and serotonin reuptake transporter on nerve |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | depression chronic anxiety
 bedwetting - imipramine
 chronic panic
 PTSD
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | no mood elevation in normal pt unmasks manic behavior in bipolar - watch out
 
 narrow theraputic index (5-6x is lethal)
 
 sedation, light headed, hypotension, weight gain
 
 anticholinergic: dry mouth, blurred vision
 
 amine inhibit and anticholinergic: postural hypotension, tachycardia, flat T wave, supress depolarization
 |  | 
        |  | 
        
        | Term 
 
        | what drugs interact with TCA, what happens |  | Definition 
 
        | quinidine class I antiarrhytmic: dangerous with flat T wave side effect 
 MAOI: HTN, convulsion, coma
 
 adrenergics: potentiate, stop amine removal
 
 ethanol: toxic sedation (CNS depression)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tranylcypromine phenelzine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mitochondria enzymes that break down dopamine and serotonin in liver and brain |  | 
        |  | 
        
        | Term 
 
        | what are the types of MAO, where are they |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | suicide inhibiton of MAO increases NT in cleft |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SSRI trazodone
 venlafaxine
 warfarin
 OTC decongestants
 tryamine
 
 cause serotonin syndrom
 |  | 
        |  | 
        
        | Term 
 
        | signs of serotoniin syndrome |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | where is tryamine found, what does it normally do in body |  | Definition 
 
        | cheese, liver, beer, wine 
 inactivated by MAO in gut
 |  | 
        |  | 
        
        | Term 
 
        | why is tryamine bad with MAOI |  | Definition 
 
        | MAO normally breaks it down so now it builds up in nerves causing headache, nausea, HTN, arrhytmia, stroke |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | 5 drugs used for manic depression |  | Definition 
 
        | lithium salts carbamazepine - anticonvulsant
 valproic acid - anticonvulsant
 gabapentin - anticonvulsant, neurotic pain relief
 risperidone
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | membrane stabilization can replace Na in AP but isnt enough to run the pumps
 
 Alters IP3
 |  | 
        |  | 
        
        | Term 
 
        | side effects of lithium salts |  | Definition 
 
        | no sedation, euphoria, depression 
 low theraputc index need to monitor blood levels
 
 nephrgenic diabetes insipidus
 contraindicated in sick sinus syndrome
 reversable hypothyroidism and goiter
 tremor
 |  | 
        |  | 
        
        | Term 
 
        | signs of lithium salt overdose |  | Definition 
 
        | seizure, circulatory collapse |  | 
        |  | 
        
        | Term 
 
        | interactions with lithium salts and their side effect |  | Definition 
 
        | thiazide diruetics MAOI- MALIGNANT HTN
 |  | 
        |  | 
        
        | Term 
 
        | define psychosis, what are signs |  | Definition 
 
        | disturbance of reality and perception impaired cognative functioning
 inappropirate or bad affect
 |  | 
        |  | 
        
        | Term 
 
        | what are causes of psychosis |  | Definition 
 
        | drug abuse dementia
 alzheimers
 schizophrenia
 |  | 
        |  | 
        
        | Term 
 
        | prognosis of schizophrenia |  | Definition 
 
        | life long, no cure need drugs all life
 usually bad compliance
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | idiopathic, shows in teens |  | 
        |  | 
        
        | Term 
 
        | what are schizophrenia drugs called on the street, man |  | Definition 
 
        | neuroleptic agents major tranquilizers
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | over action of biogenic amines as NT |  | 
        |  | 
        
        | Term 
 
        | positive symptoms of schizophrenia |  | Definition 
 
        | exaggerated distorted function hallucinations, delusions
 disorganized behavior
 |  | 
        |  | 
        
        | Term 
 
        | negative symptoms of schizophrenia |  | Definition 
 
        | loss of normal function diminished speech
 blunted emotions
 loss of energy
 inability to experience pleasure
 |  | 
        |  | 
        
        | Term 
 
        | 7 typical anti-psychotic drugs |  | Definition 
 
        | pheothiazines aliphatic - chlorpromazine
 piperazine - trifluoperazine
 fluphenazine
 pierdine - thioridazine
 butyrophenones
 thioxanthenes
 |  | 
        |  | 
        
        | Term 
 
        | what are the three most potent anti-psychotics, which is most of all |  | Definition 
 
        | piperazine - trifluoperazine butyrophenones
 fluphenazine - MOST
 |  | 
        |  | 
        
        | Term 
 
        | which anti-psychotic drugs come in depot form |  | Definition 
 
        | butyrophenones fluphenazine - MOST
 |  | 
        |  | 
        
        | Term 
 
        | in general how to typical anti-psychotics work |  | Definition 
 
        | interact with many NT systems and bind to many receptors antagonizing them |  | 
        |  | 
        
        | Term 
 
        | MOA typical anti-psychotic |  | Definition 
 
        | mostly antagonize dopamine D2 receptor (which is main one in brain) 
 physiological depolarization inactivation: initially increases firing at presynaptic neuron and later decreases release
 
 post-synaptic neuron is antagonized entire time
 |  | 
        |  | 
        
        | Term 
 
        | where are typical anti-psychotics acting |  | Definition 
 
        | mesocortical mesolimbic tract |  | 
        |  | 
        
        | Term 
 
        | how long does it take for typical anti-psychotics to work |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | reason for extra pyrmidal side effects of anti-psychotics |  | Definition 
 
        | D2 activity on motor systems |  | 
        |  | 
        
        | Term 
 
        | reversible neurological extra pyrmidal side effects of anti-psychotics |  | Definition 
 
        | acute dystonia: spasm in face, neck, back early in tx 
 akathisia: motor restlessness later in tx
 
 parkinsonism
 
 neuroleptic malignant syndrome
 |  | 
        |  | 
        
        | Term 
 
        | what is neuroleptic malignant sndrome |  | Definition 
 
        | severe parkinsons fever
 unstable BP
 |  | 
        |  | 
        
        | Term 
 
        | tx neuroleptic malignant sndrome |  | Definition 
 
        | DC anti-psychotic dantrolene
 |  | 
        |  | 
        
        | Term 
 
        | irreversible neurological extra pyrmidal side effects of anti-psychotics |  | Definition 
 
        | tarditive dyskinesia: repetitive tick like movement of face, trunk extremities |  | 
        |  | 
        
        | Term 
 
        | what agents most often cause irreversible neurological extra pyrmidal side effects of anti-psychotics |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | autonomic side effects of anti-psychotics cause |  | Definition 
 
        | a-adrenergic blocking (develop tolerance over time to it tho) |  | 
        |  | 
        
        | Term 
 
        | autonomic side effects of anti-psychotics |  | Definition 
 
        | hypotension sedation
 stroke in elderly
 |  | 
        |  | 
        
        | Term 
 
        | which antipsychotic most often causes a-adrenergic side effects, which least does |  | Definition 
 
        | thioridazine - most heloperidol - least
 |  | 
        |  | 
        
        | Term 
 
        | endocrine side effects of anti-psychotics cause |  | Definition 
 
        | block tuberoinfundibular dopamine pathway so it cannot regulate prolactin |  | 
        |  | 
        
        | Term 
 
        | endocrine side effects of anti-psychotics |  | Definition 
 
        | hyperprolactinemia weight gain
 gynecomastia
 amenorrhea galactorrhea
 |  | 
        |  | 
        
        | Term 
 
        | side effects specific to thioridazine |  | Definition 
 
        | retinal deposits cause visual impairment |  | 
        |  | 
        
        | Term 
 
        | signs of overdose of anti-psychotics |  | Definition 
 
        | conduction defects that cause ventricular arrhytmia 
 probablly taking thioridazine others dont cause it much
 |  | 
        |  | 
        
        | Term 
 
        | general MOA of atypical anti-psychotics |  | Definition 
 
        | more specific to dopamine receptors causing less extra-pyrmidal side effects |  | 
        |  | 
        
        | Term 
 
        | 6 atypical anti-psychotics |  | Definition 
 
        | clozapine risperidone
 olanzapine
 quetiapine
 paliperidone
 airiprazole
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | high affinity D4 low affinity D2, 5HT2, muscuranic, H1
 |  | 
        |  | 
        
        | Term 
 
        | side effects of clozapine |  | Definition 
 
        | stroke in elderly with dementia intermediate autonomic effects
 severe agranulocytosis so monitor WBC
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | not first line, last choice |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | clozapine analog high affinity 5HT2
 medium affinity D2
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stroke in elderly with dementia hyperglycemia and diabetes
 low extra-pyramid side effects
 minimal sedation
 increased QT (cannot use CVD)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tx negative symptoms of schizophrenia well first line therapy
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | clozapine analog high 5HT2 affinity
 intermediate D2 affinity
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stroke in elderly with dementia hyperclycemia and diebetes
 low extra-pyramid effects
 minimal sedation
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | lessen symptoms of tardive dyskinesia first line anti-psychotic
 tx negative symptoms of schizophrenia well
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | clozapineanalog high affinity 5HT2
 intermediate D2 affinity
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stroke in elderly with dementia hyperglycemia and dementia
 low extra-pyrmiad effect
 minimal sedation
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tx negative symptoms of schizophrenia well |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | active metabolite od risperidone high affinity 5HT2
 intermediate D2 affinity
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | paliperidone side effects |  | Definition 
 
        | stroke in elderly with dementia hyperglycemia and diabetes
 low extra-pyramid effect
 increased QI wave(no use un CVD)
 minimal sedation
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | first line therapy tx negative schizophrenia symptoms well
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | partial D2, 5HT2, 5HT1A agonist (kicks out full agonist lesseing effect) 
 antagonist 5HT2A, 5HT7
 
 affinity for H1, a-adrenergic, D4
 
 no affinity for cholinergic receptors
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stroke in elderly with dementia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anti-psychotic bipolar disorder
 major depression
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | receptors on GABA-Cl channel receptor complex increasing frequency of channel opening causing hyperpolarization |  | 
        |  | 
        
        | Term 
 
        | side effects of all sleep BDZ |  | Definition 
 
        | tolerance develops fast 
 increase effect of alcohol
 
 avoid in sleep apenea because it relaxes muscles of upper airway
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cannot initiate or maintain sleep (symptom not disease) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | define circadian rhythm alteration |  | Definition 
 
        | disturbance in sleep wake cycle (jet lag) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | dysfunction of sleep like partial arousal |  | 
        |  | 
        
        | Term 
 
        | what are the stages of the sleep cycle, how long, how many |  | Definition 
 
        | stages 1-4: NREM stage 5: REM
 95 min each
 4-5 per night
 |  | 
        |  | 
        
        | Term 
 
        | what are the short acting sleep BDZ, how long |  | Definition 
 
        | 3-8 hours midazolam
 triazolam
 |  | 
        |  | 
        
        | Term 
 
        | what are the intermediate acting sleep BDZ, how long |  | Definition 
 
        | 10-20 hours temazepam
 estazolam
 |  | 
        |  | 
        
        | Term 
 
        | what are the long acting sleep BDZ, how long |  | Definition 
 
        | 1-3 days quazepam
 fulrazepam
 |  | 
        |  | 
        
        | Term 
 
        | side effects of short acting BDZ for sleep |  | Definition 
 
        | Triazolam only: tolerance in days, withdrawl causes rebound |  | 
        |  | 
        
        | Term 
 
        | side effects of long acting BDZ for sleep |  | Definition 
 
        | daytime sedation hang over effect
 |  | 
        |  | 
        
        | Term 
 
        | administration of midazolam |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | peanecthetic and intraoperative medication (anterograde amnesia) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | reoccuring insomnia initiating sleep
 |  | 
        |  | 
        
        | Term 
 
        | use of intermediate BDZ for sleep |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | use of long BDZ for sleep |  | Definition 
 
        | reduce sleep induration
 decreasing waking
 increase duration
 |  | 
        |  | 
        
        | Term 
 
        | what type of drug is zolpidem |  | Definition 
 
        | imidazopyridine derivative |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds to BDZ receptor at GABA-Cl channel causing hyperpolarization 
 does not affect different stages of sleep like BDZ or barbituiates
 |  | 
        |  | 
        
        | Term 
 
        | what type od drug is zaleplon |  | Definition 
 
        | pyrazolopurimidine derivative |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds to BDZ receptor at GABA-Cl channel causing hyperpolarization 
 does not affect different stages of sleep like BDZ or barbituiates
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds to BDZ receptor at GABA-Cl channel causing hyperpolarization 
 does not affect different stages of sleep like BDZ or barbituiates
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | melatonin receptor agonist binds mT1 and MT2 receptors for melatonin
 |  | 
        |  | 
        
        | Term 
 
        | what type of drug is chloral hydrate |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | unknown activate metabolite trichloroethanol |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | minimal rebound insomnia and tolerance 
 sleep walking/activities, amnesia (increases with alcohol)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | minimal rebound insomnia and tolerance |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | NO anoxiolytic, muscle relaxant, amnesic, or abuse potential 
 do not consume alcohol
 
 decreased testosterone
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | sleep longer jet lag
 long term administration
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | sleep longer long term use
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | difficulty initiating sleep good for elderly
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | sedation in kids (dental) |  | 
        |  | 
        
        | Term 
 
        | which sleep medicine is not a controlled substance, why |  | Definition 
 
        | ramelteon: no CNS depressiing |  | 
        |  | 
        
        | Term 
 
        | which sleep medicine is affected by P450 inducers and inhibitors |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | which sleep medicine has a continous release capsule, explain how it works |  | Definition 
 
        | releases 5-10 mg immediatly and the rest over 3 h |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug that binds to the same site as the ligand and makes the same signal |  | 
        |  | 
        
        | Term 
 
        | define allosteric agonist |  | Definition 
 
        | drug that binds to different site than drug making no signal but causing drug to be more effective |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug produces lesser response than the ligand and competes for ligand site |  | 
        |  | 
        
        | Term 
 
        | define competitive agonist |  | Definition 
 
        | drug binds reversibly to receptor but increase in ligand can overcome it |  | 
        |  | 
        
        | Term 
 
        | define non-competitive agonist, what are the two types |  | Definition 
 
        | binds to receptor and prevents agonist from producing max effect 
 irreversible: more common, same receptor
 allosteric: different receptor
 |  | 
        |  | 
        
        | Term 
 
        | how can you tell if something on a graph is more potent or effective |  | Definition 
 
        | moving left on the X axis is more potent moving up on the Y axis is more effective
 |  | 
        |  | 
        
        | Term 
 
        | what does a partial agonist graph look like compared to agonist |  | Definition 
 
        | less effective shorter, less high on the Y axis
 |  | 
        |  | 
        
        | Term 
 
        | what does a allosteric agonist graph look like compared to agonist |  | Definition 
 
        | same effectiveness (height on Y axis) increased potency (more left on X axis)
 |  | 
        |  | 
        
        | Term 
 
        | what does a non-competitive agonist graph look like compared to agonist |  | Definition 
 
        | very short, sinking less effective (height on Y axis)
 less potent (more right on X axis)
 |  | 
        |  | 
        
        | Term 
 
        | what does a antagonist graph look like compared to agonist |  | Definition 
 
        | same effectiveness (height on Y axis) less potency (more right on X axis)
 |  | 
        |  | 
        
        | Term 
 
        | how does a Gs protein work |  | Definition 
 
        | activates cAMP which increases PKA |  | 
        |  | 
        
        | Term 
 
        | how does a Gi protein work |  | Definition 
 
        | decreases cAMP which decreases PKA |  | 
        |  | 
        
        | Term 
 
        | how does a Gq protein work |  | Definition 
 
        | releases IP3 and DAG IP3 releases Ca
 DAG and Ca activate PKC
 |  | 
        |  | 
        
        | Term 
 
        | what is the point of equal ionization |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what happens to an acid and base if you put it in stuff that is lower (more basic) than the pKa |  | Definition 
 
        | acid will ionize base will not ionize
 |  | 
        |  | 
        
        | Term 
 
        | what happens to an acid and base if you put it in stuff that is higher (more acidic) than the pKa |  | Definition 
 
        | acid will not ionize base will ionize
 |  | 
        |  | 
        
        | Term 
 
        | what form of a drug is best excreted |  | Definition 
 
        | WA will be excreted beter in a basic enivornment 
 WB will be excreted better in an acidic enivornment
 |  | 
        |  | 
        
        | Term 
 
        | what form of a drug is best distributed in the body |  | Definition 
 
        | the same form 
 WA likes acid
 WB likes base
 |  | 
        |  | 
        
        | Term 
 
        | what is used to fix and WB or WB drug OD |  | Definition 
 
        | NaHCO3 is used to alkalize urine and fix WA OD 
 NH3CL is used to acidify urine and fix WB OD
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | increases gene expression of P450 metabolizing enzymes which decreases the plasma level of the drug making it less effective and decreasing presence of symptoms |  | 
        |  | 
        
        | Term 
 
        | what are 5 examples of inducers |  | Definition 
 
        | rifampin, bensopyrine, chronic ethanol, phenytoin, barbituates |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | decrease gene expression for metabolizing P450 enzymes increasing plasma concentration of the drug which increases symptoms |  | 
        |  | 
        
        | Term 
 
        | what are 4 examples of inhibitors |  | Definition 
 
        | cimetidine, erythromycin, ketonazole, grapefruit |  | 
        |  | 
        
        | Term 
 
        | define first order metabolism |  | Definition 
 
        | rate of drug metabolism is proportional to concentration of the free drug constant fraction of drug is metabolized per unit time
 |  | 
        |  | 
        
        | Term 
 
        | define zero order metabolism |  | Definition 
 
        | drugs with large doses saturate metabolizing enzymes constant amount of drug is metabolized per unit time
 |  | 
        |  | 
        
        | Term 
 
        | what are 3 examples of drugs with zero order kinetics |  | Definition 
 
        | aspirin, ethanol, phenytoin |  | 
        |  | 
        
        | Term 
 
        | what is a maintience dose for, how is it calculated |  | Definition 
 
        | adjust rate so input equals rate of loss to keep a steady plasma level 
 (Cs)(Cl)/(F)
 |  | 
        |  | 
        
        | Term 
 
        | what is loading dose for, how is it calculated |  | Definition 
 
        | load initial volume of drug needed 
 (Cp)(Vd)/(F)
 |  | 
        |  | 
        
        | Term 
 
        | how long does it take to get to steady state, what is it dependent on(2) |  | Definition 
 
        | 4-5 half lives depends on half life and steady state is determined by first order kinetics
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | zidovudine lamivudine
 entricitabine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | host adds 3P then drug terminates DNA elongation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | peripherial neuropathy lactic acidosis
 marrow supression - zidovudine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | host adds 2P, drug terminates DNA elongation |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | maculopapular rash CNS effects - enfavirenz
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds reverse transcriptase causing inactivation |  | 
        |  | 
        
        | Term 
 
        | name a protease inhibitor, what is the MOA |  | Definition 
 
        | ritonavir inhibits protease stopping viral replication
 |  | 
        |  | 
        
        | Term 
 
        | protease inhibitor side effects (5) |  | Definition 
 
        | central fat deposition insulin release
 hyperglycemia
 P450 inhibitor - increased in infants
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | in combination with out PI because it is an extra good P450 inhibitor |  | 
        |  | 
        
        | Term 
 
        | name an integrase inhibitor |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibits viral genetic integration into host chromosomes |  | 
        |  | 
        
        | Term 
 
        | name three anti-herpes drugs |  | Definition 
 
        | acyclovir gencyclovir
 foscarnet
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | TK adds 1P, host adds 2P, DNA chain termination |  | 
        |  | 
        
        | Term 
 
        | acyclovir side effects (4) |  | Definition 
 
        | delerium tremor
 seizure
 nephrotoxicity (crystal urea, drink water)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | TK adds 1P, host adds 2P, DNA chain termination |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | stops reverse transcriptase and DNA polumerase |  | 
        |  | 
        
        | Term 
 
        | fascarnet side effects (2) |  | Definition 
 
        | nephrotoxicity altered Ca and P balance
 |  | 
        |  | 
        
        | Term 
 
        | what two herpes drugs treat CMV |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | name and influenza a and b drug |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | neuroaminidase inhibitor that stopps viral budding |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | stops mycolic acid assembly |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | peripherial neuritis (take B6 to fix) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | rifampin side effects (5) |  | Definition 
 
        | P450 inhibitor pseudomembrane colitis
 renal failure
 anemia
 red/orange urine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | which antibiotics should be adjusted with renal dysfunction |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit transpeptidation in cross linking |  | 
        |  | 
        
        | Term 
 
        | what are the side effects of B-lactams |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are the side effects of imipenem |  | Definition 
 
        | seizures with renal dysfunction |  | 
        |  | 
        
        | Term 
 
        | how can something become resistant to B-lactams |  | Definition 
 
        | alter PBP, product B-lactaminase |  | 
        |  | 
        
        | Term 
 
        | how can you avoid B-lactaminase |  | Definition 
 
        | clavulamic acid: B lactaminase inhibitor |  | 
        |  | 
        
        | Term 
 
        | which penicillin is the most B-lactaminase resistant, what group is it in |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | which cephalosporin is the most B-lactaminase resistant, which group is it in |  | Definition 
 
        | cephtriaxone (3 and 4th generation) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds d-alanine terminal to inhibit peptidoglycan elongation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | red man syndrome (upper body flushing due to histamin release and infusion too fast) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | altering d-alanine terminal |  | 
        |  | 
        
        | Term 
 
        | tetracyclines work on what subunit |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are two tetracyclines |  | Definition 
 
        | tetracycline + docycycline |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | unable to bind receptor site |  | 
        |  | 
        
        | Term 
 
        | tetracycline side effects |  | Definition 
 
        | metals (antacids) cause chelation concentrations in bone and teeth
 phototoxicity
 |  | 
        |  | 
        
        | Term 
 
        | aminoglycosides work on what subunit |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are two aminoglycosides |  | Definition 
 
        | doxycycline and gentamycin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | need O2 to get into bacteria (will never work on anaerobes) |  | 
        |  | 
        
        | Term 
 
        | aminoglycocide side effects |  | Definition 
 
        | nephrotoxicity ototoxiticy
 muscle weakness due to decreased ACh release
 |  | 
        |  | 
        
        | Term 
 
        | macrolides work on what subunit |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are three macrolides |  | Definition 
 
        | erythromycin, azithromycin, clathromycin |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | bind to motilin receptor increasing GI motility (used in gastroperosis in diabetics) |  | 
        |  | 
        
        | Term 
 
        | what drug is an antifolate |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | pteridine + PABA use DHPS to make DHF 
 DNF uses DHFR to make THF
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit DHPS (dihydrofolate synthase) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit dihydrofolate reductase (DHPR) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | hypersensitivity, SJS in G6PDH deficiency get hemolytic anemia
 marrow supression because it stops THF causing anemia
 phototoxicity
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | ciproflaxcin and levoflaxcin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit topoisomerae 2 (DNA gyrase) stopping positive supercoils |  | 
        |  | 
        
        | Term 
 
        | flouroquinolone side effects |  | Definition 
 
        | tendon and cartiladge: tendinitis, tears 
 phototoxicity
 |  | 
        |  | 
        
        | Term 
 
        | function of flouroquinolones |  | Definition 
 
        | kill all geam negatives levoflaxcin kills gram positive too (good for atypical pneumonia)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cannot have O2 present (works on anaerobes only) |  | 
        |  | 
        
        | Term 
 
        | side effects metronidazole |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | giardia entomebia
 trichomonas
 bacterioides
 clostridium
 gardnerella
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | doxycyclin or azithromycin |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | pen G if using a cephalosporin: cephalexin
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anti-steph penicillin (naficillin) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | tetracycline or macrolide |  | 
        |  | 
        
        | Term 
 
        | what microbes cause atypical pneumonia |  | Definition 
 
        | chalmydia mycoplasma
 legionella
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cephtriaxone (+ampicillin for listeria) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | binds ergosterol opening pores killing fungi |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | serious systemic infection, too toxic for regular use |  | 
        |  | 
        
        | Term 
 
        | amphotericin B side effects |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | fluconazole and voraconazole MOA |  | Definition 
 
        | inhibit 14a-demythelase stopping lenosterol conversion to ergosterol |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | routine fungal infection less serious fungal infection
 anti-fungal (candidia)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | stops squaline exopidase stopping squaline conversion to squaline epoxidase |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | dermatophic infection (tinea), oncomycosis (nails) |  | 
        |  | 
        
        | Term 
 
        | terbinafine administration |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | prophylaxis and tx DOC for blood schizonticide (malaria in blood) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | add to chloroquine for p. vivax and p. ovale because they chill in liver (tissue schizonicide) |  | 
        |  | 
        
        | Term 
 
        | side effects of primaquine |  | Definition 
 
        | in people with G6PDH deficiency causes hemolytic anemia |  | 
        |  | 
        
        | Term 
 
        | explain the process of cholinergic activation up until NT release |  | Definition 
 
        | 1. Uptake of choline via Na cotransport RATE LIMITING 2. Choline acetyl transferase (CAT) and acetylCoA synthesizes acetylcholine
 3. Storage of acetylcholine inside vesicle and H+ is effluxed
 4. Depolarization: Ca channels open and  lets Ca in
 5. Ca mediated vesicle fusion: vesicles migrate and fuse to release contents
 |  | 
        |  | 
        
        | Term 
 
        | what are the fates of ACh after release from neuron |  | Definition 
 
        | a. Diffuse across synapse and bind to post-synaptic receptor (N or M) or pre-synaptic receptor (M) b. Bind to pre-synaptic auto receptor for negative feedback
 c. Rapidly metabolized by acetylcholinesterase into acetate and choline which is taken back into nerve (Causes short half-life)
 |  | 
        |  | 
        
        | Term 
 
        | explain how the pre-synaptic autoreceptor works |  | Definition 
 
        | i. M2 receptor on original nerve ii. Inhibitory Gi protein causes cAMP to go down and Ca channels close
 iii. Stopping release of neurotransmitter
 |  | 
        |  | 
        
        | Term 
 
        | botox: where does it come from, what does it do |  | Definition 
 
        | Produced by clostrum botulinium 
 Gets inside nerve and inhibits vesicles from fusing with membrane
 
 Blocks release of ACh
 |  | 
        |  | 
        
        | Term 
 
        | latrotoxin: where does it come from, what does it do |  | Definition 
 
        | Spider venom 
 Causes flood of ACh to be released
 |  | 
        |  | 
        
        | Term 
 
        | muscarinic receptors: innervated by, NT is |  | Definition 
 
        | Cholinergic receptor on end organ 
 Affinity for ACh and agents that mimic ACh (cholinomimetics)
 |  | 
        |  | 
        
        | Term 
 
        | what does a muscarinic receptor have the highest affinity for |  | Definition 
 
        | Highest affinity for muscarine (in poisonous mushrooms) |  | 
        |  | 
        
        | Term 
 
        | in one sentence describe the purpose of muscarinic receptors |  | Definition 
 
        | Innervate parasympathetic nervous system effects onHeart, smooth muscle, endocrine glands |  | 
        |  | 
        
        | Term 
 
        | where is m1 located, what type of receptor |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | phospholipase C > PIP2 > IP3 + DAG |  | 
        |  | 
        
        | Term 
 
        | where is m2 receptor located |  | Definition 
 
        | heart 
 Auto receptors on pre/post-ganglionic or pre-synaptic  cholinergic nerves
 |  | 
        |  | 
        
        | Term 
 
        | what type of receptor is m2, how does it work |  | Definition 
 
        | Gi receptor 
 Heart: decrease K+ conductance
 
 Presynaptic: decreases cAMP
 |  | 
        |  | 
        
        | Term 
 
        | in general, what do M2 receptors do |  | Definition 
 
        | Decreases HR and force of contraction (due to decreased K conductance) 
 Decreases ACh release
 |  | 
        |  | 
        
        | Term 
 
        | where are m3 receptors located, what type of receptor, what do they do |  | Definition 
 
        | everywhere but heart and brain 
 Gq receptor
 
 constrict smooth muscle
 |  | 
        |  | 
        
        | Term 
 
        | where are m4 receptors, what type of receptor |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | where are m5 receptors, what type of receptor |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what does a muscarinic agonist do |  | Definition 
 
        | stimulate muscarinic receptor by mimicing ACh but with longer half life |  | 
        |  | 
        
        | Term 
 
        | why do muscarinic receptor agonists have a longer half life |  | Definition 
 
        | no acetylcholinesterase issue they only do M receptor (not n) so fewer side effects and uptake issues
 |  | 
        |  | 
        
        | Term 
 
        | what are the 4 muscarinic agonists and their relative nicotinic effects |  | Definition 
 
        | bethanechol - little carbachol - lots causes SE
 methacholine - little
 pilocarpine
 |  | 
        |  | 
        
        | Term 
 
        | what does benthanecol work on |  | Definition 
 
        | stimulates GI and urinary tract |  | 
        |  | 
        
        | Term 
 
        | how is bethanecol administered, why |  | Definition 
 
        | oral, because it isnt absorbed well and limits SE |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | postop and post partum non-obstructive urinary retention 
 neurogenic atony of bladder with retention
 
 gastric atony
 
 urinary retention; caused by diabetic lack of GI tone, decreased bladder tone due to drugs (ANTI-PSYCHOTICS) ith anti-muscarinic effects
 |  | 
        |  | 
        
        | Term 
 
        | what is carbachol used for |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is methacholine used for |  | Definition 
 
        | bronchoconstriction - diagnostic for subclinical asthma 
 methacholine challenge test; asthma pt is more sensitive to methacholine induced bronchoconstriction
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stimulate salivary secretion |  | 
        |  | 
        
        | Term 
 
        | what are the ways pilocarpine is administered, why for each (3) |  | Definition 
 
        | IV/IV: it isnt, this increases toxicity topical: reduce side effects (eye drops)
 oral: xerostomia (increased SE)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | openangle and closed angle glaucoma: increases aq humor drainage and decreased production 
 xerostoma
 |  | 
        |  | 
        
        | Term 
 
        | what causes xerostomia, what is it |  | Definition 
 
        | difficulty swallowing due to head and neck radiation or sjogerns |  | 
        |  | 
        
        | Term 
 
        | what is sjogerns and what are the symptoms |  | Definition 
 
        | autoimmune disease decreased secretions: lacrimation, saliva, vaginal
 |  | 
        |  | 
        
        | Term 
 
        | effects of muscarinic agonist on GI tract |  | Definition 
 
        | increase tone, constraction, peristalsis, secretions 
 nausea, belching vomiting, intestinal cramps, defecation
 |  | 
        |  | 
        
        | Term 
 
        | effects of muscarinic agonist on urinary tract |  | Definition 
 
        | increase urethral peristalsis contract detrusor
 relax trigone and sphincter
 increase voiding pressure
 decrease capacity of bladder
 |  | 
        |  | 
        
        | Term 
 
        | effects of muscarinic agonist on cardiovascular system |  | Definition 
 
        | decrease HR - neg chronotrophic decrease conduction at SA/AV - negative domotrophic
 decrease contraction force (neg inotrophic)
 vasodilation
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | conduction at SA/AV nodes |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | explain how muscarinic agonist cause vasodilation |  | Definition 
 
        | Vessels have M3 receptors on endothelial cells WITHOUT nerve attached (no physiological purpose!) 
 if you could activate them they release NO causing vasodilation (because the receptor is on endothelial cells DIFFERENT CELL TYPE = DIFFERENT RESPONSE)
 |  | 
        |  | 
        
        | Term 
 
        | what is the overall cardiovascular response to the changes muscarinic agonist make |  | Definition 
 
        | decreased HR, conduction, force, vasodilation causes decreased BP 
 sympathetic responds to this increasing BP
 |  | 
        |  | 
        
        | Term 
 
        | what is the effect of muscairinic agonist on secretions, sweat, lungs, eyes |  | Definition 
 
        | increase secretions: salivary, lacrimal, digestive, exocrine, tracheobronchial 
 sweat glands: (sympathetic but have non innervated M3)
 
 bronchoconstriction
 
 miosis and accommodation for near vision
 
 stimulate chemoreceptors on carotid and aortic bodies
 |  | 
        |  | 
        
        | Term 
 
        | side effects of muscarinic agonist |  | Definition 
 
        | miosis, bradycardia, bronchoconstriction (avoid in asthma), increased gastric acid (avoid in ulcers), diarrhea, urination 
 flushing: due to vasodilation increasing blood flow
 
 salivation, lacrimation, sweating (sympathetic!!)
 |  | 
        |  | 
        
        | Term 
 
        | what are the antidotes to musarinic OD |  | Definition 
 
        | atropine sulfate - muscarinic antagonist 
 epinepherine
 |  | 
        |  | 
        
        | Term 
 
        | atrophine sulfate: admninistration, use |  | Definition 
 
        | IV/SC treat toxic reaction of muscarinic agonist
 |  | 
        |  | 
        
        | Term 
 
        | how does epinepherine work |  | Definition 
 
        | physiologic antagonist works on different receptor overcomes cardiovascular and bronchoconstrictor receptors
 |  | 
        |  | 
        
        | Term 
 
        | reversible acetylcholinesterase inhibitor |  | Definition 
 
        | breaks down acetylcholinesterase and increases M and N receptor action all over body in parasympathetic, sympathetic, and somatic NS |  | 
        |  | 
        
        | Term 
 
        | reversible acetylcholinesterase inhibitor drugs (8) |  | Definition 
 
        | physpstigmine pyridostigmine
 neostigmine
 edrophonium
 ambenomium
 donpezil
 rivastigmine
 galatamine
 |  | 
        |  | 
        
        | Term 
 
        | irreversible acetylcholinesterase inhibitor drugs (6) |  | Definition 
 
        | military nerve agents: sarlin nerve gas, soman, tabun 
 insecticides: parathion, malathion (organophosphates)
 
 lice topical: malathion
 |  | 
        |  | 
        
        | Term 
 
        | acetylcholinesterase inhibitor antidotes (2) |  | Definition 
 
        | pralidoxime (PAM) atropine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stimulates Nn and Nm receptors activates sympathetic and parasympathetc NS (mostly parasympathetic)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | cholinergic antagonist MOA |  | Definition 
 
        | binds to cholinergic receptors and stops ACh stops parasympathetic and muscarinic transmission
 |  | 
        |  | 
        
        | Term 
 
        | what are the two types of cholinergic antagonists and their general function |  | Definition 
 
        | ganglionic blockers: show preference for blocking nicotonic of sympathetic and parasympathetic GANGLIA 
 NMJ blockers: block different impulses to SKELETAL MUSCLE
 
 antimuscarinic and antinicotinic
 |  | 
        |  | 
        
        | Term 
 
        | MOA of antimuscarinic agents |  | Definition 
 
        | block M receptors blocking parasympathetic and sympathetic NS mediated by ACh (thats sweating for sympathetic) 
 no nicotinic receptor activation
 
 competitive agonist - can be out competed
 
 target organ depends on lipid solubility
 |  | 
        |  | 
        
        | Term 
 
        | what are competitive muscarinic agonists / muscarinic antagonist antidotes |  | Definition 
 
        | thiostigmine, ACh inhibitor, muscarinic agonist |  | 
        |  | 
        
        | Term 
 
        | what strucure of antimuscarinic agents makes it more lipid soluble, what diseases is this required for |  | Definition 
 
        | qaternary N is more polar and less likley to penetrate BBB or cornea so needs to have tertiary amine 
 parkinsons and opthalmology needs lipid soluble (gut and bronchi dont)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tropicaamide scopolamide
 bnstropine
 atropine
 tolterodine
 oxybutynin
 |  | 
        |  | 
        
        | Term 
 
        | physpstigmine distribution |  | Definition 
 
        | tertiary amine: lipid soluble |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antidote for muscarinic blockers (anticholinergic toxicity) like atropine 
 reversible acetylcholinesterase inhibitor
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | pyridostigmine/neostigmine MOA |  | Definition 
 
        | quarinary amine (positive) water soluble 
 only used for Nm at NMJ
 
 reversible acetylcholinesterase  inhibitor increases ACh can outcompete binding of antibodies in myasthenia gravis
 |  | 
        |  | 
        
        | Term 
 
        | use pyridostigmine/neostigmine |  | Definition 
 
        | myasthenia gravis: autoimmune disease with antibodies to Nm causes weakness mostly in facial region, the more they excert the weaker they get, symptoms improve with rest 
 reversal of non-depolarizing blocking agents like tubocurarine
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | IV short acting 10-20min reversible acetylcholinesterase inhibitor to diagnose myasthemia gravis if muscle activity returns then they have it
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | back up drug for myasthenia gravis if they cannot tolerate bromides |  | 
        |  | 
        
        | Term 
 
        | donepezil/rivastigmine/galantamine distribution |  | Definition 
 
        | tertiary amines: enter CNS |  | 
        |  | 
        
        | Term 
 
        | donepezil/rivastigmine/galantamine use |  | Definition 
 
        | alzheimers (mostly doneprezil) 
 neurodegenerative disorder with loss of memory and cognative function
 pt looses cholinergic neurons in cortex (mynert's nuclei)
 
 increasing ACh is many strategy for tx
 |  | 
        |  | 
        
        | Term 
 
        | parathion/malathion: MOA, SE, use |  | Definition 
 
        | insecticides, malathion is for lice 
 prodrugs, activated by P450
 
 active form is hydrolyzed by plasma carbxylesterases which causes death in insects but sucks in us only in high doses
 |  | 
        |  | 
        
        | Term 
 
        | SE acetylcholinesterase inhibitors and the receptor involved |  | Definition 
 
        | diarrhea - M3 urination - M3
 miosis - M3
 bronchoconstriction - M3
 bradycardia - M2
 excitation of skeletal M - Nm
 excitation of CNS - M1, Nn
 lacrimation - M3
 salivation - M3
 sweating - M3 - sympathetic!
 |  | 
        |  | 
        
        | Term 
 
        | what SE of acetylcholinesterase inhibitors are deatly |  | Definition 
 
        | excitation of skeletal muscle / CNS 
 causes paralysis of diaphragm
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | breaks bone between irreversible acetylcholinesterase inhibitor and ACh, regenerating the enzyme so it can work again |  | 
        |  | 
        
        | Term 
 
        | what is chemical aging, why is it a problem |  | Definition 
 
        | change in structure of irreversible acetylcholinesterase inhibitor makes it so pralodoxime can no longer remove the drug 
 due to hydrolysis reaction pulling alkyl grop off
 
 rate depends on agent - can be minutes
 
 releases enzyme so it breaks down ACh and stops effects at skeletal M
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibits everything in acetylcholinesterase SE except excitation of heart |  | 
        |  | 
        
        | Term 
 
        | nicotinic receptors: MOA, locations, types |  | Definition 
 
        | binds ACh and nicotine nitotine initially stimulates then blocks receptor
 
 locations: CNS, adrenal medulla, autonomic ganglia, NMJ
 
 types: autonomic ganglia Nn, skeletal muscle Nm
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stimulates Nn and Nm receptors stimulating parasympathetic and sympathetic (vessels, and sweating)
 |  | 
        |  | 
        
        | Term 
 
        | SE/MOA high doses of nicotine |  | Definition 
 
        | desensitization of receptors at organs leads to inability to cause parasympathetic response and thus causes sympathetic response |  | 
        |  | 
        
        | Term 
 
        | what causes problems in cigarette smoke, why |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | MOA cholinergic antagonist |  | Definition 
 
        | blinds to cholinergic receptor stopping ACh stopping parasympathetic and muscarinic transmission |  | 
        |  | 
        
        | Term 
 
        | types of cholinergic antagonists |  | Definition 
 
        | ganglionic blockers NMJ blockers
 |  | 
        |  | 
        
        | Term 
 
        | where does atropine come from |  | Definition 
 
        | belladone aklaloid, gymsin weed |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | blocks receptors in PNS and CNS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tertiary amine: lipid soluble, enters CNS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | short 4-8h unless in eye 3-5d
 |  | 
        |  | 
        
        | Term 
 
        | CNS effects of antimuscarinic |  | Definition 
 
        | sedation, anti-motion sickness, anti-parkinsons, amnesia, delirium |  | 
        |  | 
        
        | Term 
 
        | M1 effecs of antimuscarinic |  | Definition 
 
        | GI relaxation, slow peristalsis 
 exocrine: reduced salivation, lacrimation, sweating, gastric secetion
 |  | 
        |  | 
        
        | Term 
 
        | M2 effects of antimuscarinic |  | Definition 
 
        | heart: initial bradycardia then tachycardia decreases in AV conduction 
 inhibit presynaptic M2 (inhibit inhibitory) and pathway becomes stimulate releasing more ACh -> initial bradycardia
 
 M2 acts on heart a little more slowly and blocks it -> tachycardia
 |  | 
        |  | 
        
        | Term 
 
        | effects of antimuscarinic on M3 |  | Definition 
 
        | eye: cycloplegia bronchi: dilation
 GI: relaxation, slow peristalsis
 GU: relax bladder wall, urinary retention
 vessesl: block muscarinic causing vasodilation (only when muscarinic agonist present or else does nothing)
 exocrine: reduced salivation, lacrimation, sweating, gastric secretion
 |  | 
        |  | 
        
        | Term 
 
        | SE of antimuscarinic - hot as a pistol |  | Definition 
 
        | atropine fever: blocks thermoregulatory mechanisms causing hyperthermia (lethal in infants) |  | 
        |  | 
        
        | Term 
 
        | SE of antimuscarinic - dry as a bone |  | Definition 
 
        | decreased sweating, lacrimation, salivation, urination, pooing |  | 
        |  | 
        
        | Term 
 
        | SE of antimuscarinic - blind as a bat |  | Definition 
 
        | blurred bision, acute angle closure glaucome (esp elderly) |  | 
        |  | 
        
        | Term 
 
        | SE of antimuscarinic - mad as a hatter |  | Definition 
 
        | sedation, amnesia, delirium, hallucinations |  | 
        |  | 
        
        | Term 
 
        | SE of antimuscarinic - red as a beet |  | Definition 
 
        | atropine flush: dilation of cutaneous vessels in arms, head, neck, trunk 
 diagnostic for OD
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | dilate pupil (mydriasis) for eye exam paralyze accomodation
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | motion sickness - block receptors in vestibular apparatus that induce nausea and vomiting |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | adjunct to L DOPA for parkinsonism (loss of dopaminergic neurons decreases dopamine and increases ACh) |  | 
        |  | 
        
        | Term 
 
        | what drug can help with peptic ulcer disease |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what drug can be used for bronchodilation in asthma and COPD |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | use of tolerodine, oxybutynin, |  | Definition 
 
        | reduce urgency in cystitis reduce bladder spasm following urologic surgery
 urinary incontence
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | block Nn receptor on autonomic ganglia and adrenal medulla blocks dominant system (usually parasympathetic)
 |  | 
        |  | 
        
        | Term 
 
        | ganglionic blocker drug and its use and MOA |  | Definition 
 
        | mecamylamine HTN back up drug
 decrease sympathetic tone and vasodilates
 |  | 
        |  | 
        
        | Term 
 
        | structure of neuromuscular blockers |  | Definition 
 
        | similar to ACh have 2 quatenary N, unable to get in CNS
 |  | 
        |  | 
        
        | Term 
 
        | uses of neuromuscular blockers |  | Definition 
 
        | surgical relaxation trachea intubation
 control ventilation
 control motor acrivity in seizure (not tx it)
 |  | 
        |  | 
        
        | Term 
 
        | what category of drugs are best at helping with trachea intubation |  | Definition 
 
        | depolarizing neuromuscular blockers |  | 
        |  | 
        
        | Term 
 
        | MOA non-depolarizing neuromuscular blockers |  | Definition 
 
        | competitive blocker of ACh and Nm receptor at a subunit 
 can be outcompeted by acetylcholinesterase inhibitors
 |  | 
        |  | 
        
        | Term 
 
        | what is the antidote to non-depolarizing neuromuscular blocker |  | Definition 
 
        | acetylcholinesterase inhibitors neostigmine and pyridostigmine (because they work in peripherary) |  | 
        |  | 
        
        | Term 
 
        | side effect of all non-depolarizing neuromuscular blockers |  | Definition 
 
        | motor weakness: small muscles first then large, large first to recover diaphragm is last
 |  | 
        |  | 
        
        | Term 
 
        | what are the short duration neuromuscular blockers, how long |  | Definition 
 
        | 10 min articurium
 mivacurium
 |  | 
        |  | 
        
        | Term 
 
        | what are the intermediate duration neuromuscular blockers, how long |  | Definition 
 
        | 25 min cisatracurium
 rochuronium
 |  | 
        |  | 
        
        | Term 
 
        | what are the long duration neuromuscular blockers, how lonw |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | spontaneously inactivate to metabolite laudanosine (causes seizures, can be used in liver and kidney dysfynction) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | same as articurium but when spontaneously inactivated does not produce as much laudanosine so less seizures occur |  | 
        |  | 
        
        | Term 
 
        | mivacurium SE, duration, onset of action |  | Definition 
 
        | shortest DURATION short onset of action
 
 causes histamine release > hypotension and reflex tachycardia
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | blocks M receptors and causes tachycardia |  | 
        |  | 
        
        | Term 
 
        | what drug is a depolarizing neuromuscular blocker, what is its structure |  | Definition 
 
        | succinylcholine - 1 ACh together |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | phase one: simulates ACh and causes muscle contraction 
 phase two: overstimulation causes de-sensitization of the receptor so membrane repolarizes but it cannot easily repolarize
 |  | 
        |  | 
        
        | Term 
 
        | what is the antidote for succinylcholine |  | Definition 
 
        | there isnt one. acetylcholinesterase innhibitor dosent work. 
 it increases ACh in the phase one which just further mimics the drug
 
 it increases ACh in phase two but at that point it dosent matter how much ACh there is, the receptor dosent work
 |  | 
        |  | 
        
        | Term 
 
        | kinetics and distribution succinylcholine |  | Definition 
 
        | short acting, works fast less lipid soluble, cannot get into CNS
 |  | 
        |  | 
        
        | Term 
 
        | succinylcholine: how long does it take to work, wat are the next two stages of timing, how long does it take to stop, why does it stop |  | Definition 
 
        | 30s- general anasthesia 90s- arm, back, leg muscle flaccid
 more sec- repsiratory muscle flaccid
 10 min- hydrolyzed in plasma and liver cholinesterase
 |  | 
        |  | 
        
        | Term 
 
        | side effects of depolarizing neuromuscular blockers, why |  | Definition 
 
        | can stimulate M and Nn too causing bradycardia 
 hyperkalemia in burn pt, head injury, trauma bc Na rushes in and K out at nicotinic receptors which are being fired
 
 muscle pain due to initial contraction
 
 increased risk if inhaled anasthetic
 |  | 
        |  | 
        
        | Term 
 
        | interactions with depolarizing neuromuscular blockers, effect, tx |  | Definition 
 
        | inhaled anasthetics: malignant hyperthermia (rare, fatal). due to abnormal release of Ca from skeletal M 
 tx dantrolene
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | blocks ryanoide receptor (RyR1) on SER blocking Ca release decreasing ability for contraction 
 decreased muscle contraction decreases body temo
 |  | 
        |  | 
        
        | Term 
 
        | what tx malignant hyperthermia, how is the condition started |  | Definition 
 
        | dantrolene genetic alteration in RyR1 gene + succinylcholine or anesthetics --> prolonged Ca release --> muscle contraction, lactic acid, increased body temp
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | local facial injection spasticity - cerebral palsy
 strabismus
 blepharospasm
 hyperhidrosis
 migraines
 |  | 
        |  | 
        
        | Term 
 
        | use of CNS skeletal relaxants |  | Definition 
 
        | spasticity: increase in tonic stretch reflexes. caused by spinal injury, cerebral palsy, MS, stroke 
 often involves abnormal function of bladder and bowel
 |  | 
        |  | 
        
        | Term 
 
        | how are BDZ dosed for their usages |  | Definition 
 
        | low: anxiety med: slwwp
 high: anasthetic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | activate GABAa which increases frequency of Ca channel opening decreasing neuron activity |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | activate GABAb opening K channel causing hyperpolarization and inhibiting neuron activity 
 prevent post synaptic propogation of AP
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | less sedating than diazepam |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a2 agonist: prevents NT release (glutamate presynaptic, AP post synaptic)
 
 classif autoreceptor mecanism
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | fewer effects than clonidine and methyldopa (a2 agonist for HTN) 
 hypotension and drowsiness due to decreased NE release
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | slow progression of amytrophic lateral sclerosis (ALS) / Lou Gherig's |  | 
        |  | 
        
        | Term 
 
        | what are the CNS muscle relaxants |  | Definition 
 
        | riluzole tyanadine
 baclofen
 diazepam
 |  | 
        |  | 
        
        | Term 
 
        | what does the CNS include |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are the components of the peripherial nervous system |  | Definition 
 
        | afferent: nerves going to CNS efferent: nerves leaving CNS
 |  | 
        |  | 
        
        | Term 
 
        | what is the function of afferent nerves |  | Definition 
 
        | carry information to CNS for processing autonomic nervous system reflexes: baroreceptor, emotional
 |  | 
        |  | 
        
        | Term 
 
        | compare preganglionic and poste ganglinic neuron cell bodies and axons |  | Definition 
 
        | pre: cell body in CNS, non myelinated 
 post: cell body in ganglia, non-myelinated, terminates in effector organ
 |  | 
        |  | 
        
        | Term 
 
        | function and nerve lay out of somatic NS |  | Definition 
 
        | vountary control of sksletal muscle one neuron, no ganglia
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | involuntary control of heart, vessels visceral organs, glands |  | 
        |  | 
        
        | Term 
 
        | what are the three types of input into the autonomic NS, explain where each comes from or is processed |  | Definition 
 
        | afferent sign: travels to integrating center in hpothalamus, medulla, spinal cord 
 reflexes: dont involve processing (baroreceptor increases symp and decreases para to heart)
 
 emotions; stimulate sympathetic and parasympathetic
 |  | 
        |  | 
        
        | Term 
 
        | where do sympathetic preganglionic fibers come from, where do they go |  | Definition 
 
        | T1-2, L1-5 synapse in sympathetic chain, post ganglionic extend to viscera |  | 
        |  | 
        
        | Term 
 
        | explain the wiring of the adrenal medulla |  | Definition 
 
        | recieves sympathetic preganglionic fiber that does not synapse in sympathetic chain and has no postganglionic fiber 
 instead releases hormones (N/NE) into the blood
 |  | 
        |  | 
        
        | Term 
 
        | general function of sympathetic NS |  | Definition 
 
        | continously active to maintain tone functions as a unit
 not essential for life
 fight or flight
 |  | 
        |  | 
        
        | Term 
 
        | sympathetic effect on: heart, energy, blood, pupil, lungs, bladder, GU, salivation, GI, muscle |  | Definition 
 
        | increases HR, BP energy mobilization
 blood to skin and organs decreased
 dilation of skeletal muscle vessels
 dilation of pupil
 bronchi constriction
 bronchiole dilation
 detrusor relaxation
 construction of trigone and sphinctor
 thick salivation
 decrease in gastric motility
 uterus relaxation
 ejaculation
 |  | 
        |  | 
        
        | Term 
 
        | where do parasympathetic NS fibers come from, where do they go |  | Definition 
 
        | CN III, VII, IX, X, S2-4 synapse at ganglia near effector organ
 |  | 
        |  | 
        
        | Term 
 
        | general functions of parasympathetic NS |  | Definition 
 
        | essential for life effects specific effector organ
 rest and digest
 |  | 
        |  | 
        
        | Term 
 
        | effect of parasympathetic on: eye, lung, bladder, GU, salivation, heart, GI |  | Definition 
 
        | constrict iris constricts pupil constriction of ciliary m. for near vision
 constriction of bronchioles
 contraction of detrusor
 relaxing trigone and sphinctor
 erection
 watery salivation
 decreased HR, CO
 GI motility
 |  | 
        |  | 
        
        | Term 
 
        | what are the effects when an organ has parasympathetic and sympathetic innervation |  | Definition 
 
        | parasympathetic predominates sympathetic only predominates if it is the only innervator
 |  | 
        |  | 
        
        | Term 
 
        | where is sympathetic the only innervator |  | Definition 
 
        | blood vessels, adrenal medulla, pilomotor muscles, sweat glands |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | ACh releasing NT binds to cholinergic receptor (Nm, Nn, M) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | NE releasing and NT binds to adrenergic receptor (a and B) |  | 
        |  | 
        
        | Term 
 
        | what are the two types of parasympathetic receptor/NT combinations, where are they located |  | Definition 
 
        | preganglionic/postganglionic synapse: ACh/Nn 
 postganglionic/cardiac, smooth muscle, glands synapse: ACh/M
 |  | 
        |  | 
        
        | Term 
 
        | what are the 4 types of sympathetic receptor/NT combinations, where are they located |  | Definition 
 
        | preganglionic/postganglionic: ACh/Nn 
 postganglionic/sweat gland synapse: ACh/M
 
 postganglionic/cardiac M, smooth M, gland synapse: NE/a or B
 
 postganglionic / renal vascular smooth muscle synapse: D/D1 (dopamine is precursor for NE, D1 is main periphery dopamine receptor)
 |  | 
        |  | 
        
        | Term 
 
        | what is the neuromumoral receptor/NT combination, where is it located |  | Definition 
 
        | preganglionic/adrenal medulla synapse: ACh/Nm causes release of E and NE into blood |  | 
        |  | 
        
        | Term 
 
        | what is the somatic receptor/NT synapse, where is it located |  | Definition 
 
        | somatic/skeletal muscle synapse: ACh/Nm |  | 
        |  | 
        
        | Term 
 
        | what are the three categories of chemical signalers |  | Definition 
 
        | local hormones
 neurotransmitters
 |  | 
        |  | 
        
        | Term 
 
        | local signalers: 2 examples, down side |  | Definition 
 
        | rapidly destoried or removad histamine, prostaglandin
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | travel in blood to effect broadly distributed target cells |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | communication between neurons acts on specific cellular receptor |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | cholinergic neurons in sympathetic, parasympathetic, and adrenal medulla iin all NMJ
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | adrenergic neurons, nerve transmission E from adrenal medulla into blood and activates non-adrenergic receptors
 |  | 
        |  | 
        
        | Term 
 
        | octerotide: duration, type of drug, function, use |  | Definition 
 
        | long acting somatostatin analog
 inhibits GH, glucagon, insulin, gastrin
 
 acromeagly, carcinoid
 |  | 
        |  | 
        
        | Term 
 
        | desmopressin: type of drug, MOA, use |  | Definition 
 
        | ADH analog V2 agonist
 
 central diabetes insipidus (ADH replacement)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | what drugs are used for insulin replacement therapy, how |  | Definition 
 
        | lispro: mealtime glargine: basal
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | K channel blocker leads to increased insulin release from B cells 
 SE: hypoglycemia, weight gain
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit gluconeogenesis in liver 
 no hypoglycemia or weight gain
 SE: rare lactic acidosis in pt with renal dysfunction because drug accumulates
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | insulin sensitizer: stimulate PPARy receptors which increase number of insulin receptors on many organs (like skeletal M) 
 edema, weight gain
 |  | 
        |  | 
        
        | Term 
 
        | what diabetes drugs target pancreas, MOA |  | Definition 
 
        | GLP-1 is an incretin that causes insulin release exenatide is a GLP-1 analog
 incretins are metabolized to inactive by DPP-4
 sitaglipdin is a DPP-4 antagonist
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | T4 agonist needs to be converted to T3 
 hypothyroid
 |  | 
        |  | 
        
        | Term 
 
        | methinizaole: MOA, SE, use |  | Definition 
 
        | blocks all the steps in thyroid hormone synthesis 
 iodide conversion to iodine via thyroid peroxidase
 peroxidase conversion to MIT/DIT making T3/4
 
 SE: agranulocytosis
 
 TX: hyperthyroid
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | thyroid sucks it up and B radiation destories thyroid 
 TX hyperthyroid
 
 not for pregnant and kids
 |  | 
        |  | 
        
        | Term 
 
        | explain the glucocordicoud/mineral corticoid activity of the three steroids |  | Definition 
 
        | hydrocortizone: 1:1 dexamethasone: 1:0
 flucortizone: 10:250
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | adrenal insufficiency congenital adrenal hypothyroid
 after cushing surgery
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | aldosterone: Na/water retention, edema, increased BP 
 glucacorticoid: cushing like, ulcers
 |  | 
        |  | 
        
        | Term 
 
        | use of conjugated equine estrogen |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | oral contracepitive hormone replacement
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | progesterone receptor blocker abortion (when added with prostaglandins)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 5a reductase inhibitor stops testosterone conversion to DHT 
 BPH, balding
 |  | 
        |  | 
        
        | Term 
 
        | when can't you use finastride |  | Definition 
 
        | a1 blocker and a1A blocker both treat BPH if pt needs to lower BP then don;t choose finasteride
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | androgen receptor blocker (used with GNRH agonist continous administration( 
 prostate cancer
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | PDE3 inhibitor increases cAMP: relaxes, vasodilates, increases blood flow 
 erectile dysfunction
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | dont take with nitrates or a blockers (which are also vasodilators and cause orthostatic hypotension) 
 hypotension
 
 PDE6 inhibition causes blue green color blidness
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | hypocalcemia (tetany, M spasms) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1,25-dihydroxy vitamin D in active form 
 rickets, osteomalacia, osteoperosis
 |  | 
        |  | 
        
        | Term 
 
        | alendronate: MOA, use, SE |  | Definition 
 
        | decrease bone reabsorption 
 TX: osteoperosis DOC, pagets disease
 
 SE: esophageal irritation (stay upright after taking)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | selective estrogen receptor modulator, agonist on bone, antagonist on breast and uterus 
 antagonist at uterus DOES NOT give increased risk of endometrial cancer (like tamoxifin)
 
 TX: osteoperosis, breast cancer
 |  | 
        |  |